Cobimetinib Fumarate Patent Expiration
Cobimetinib Fumarate is used for the treatment of adult patients with histiocytic neoplasms and melanoma. It was first introduced by Genentech Inc
Cobimetinib Fumarate Patents
Given below is the list of patents protecting Cobimetinib Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cotellic | US10478400 | Immediate-release tablets containing combimetinib and methods of making and using the same | Jun 29, 2036 | Genentech Inc |
| Cotellic |
US10478400 (Pediatric) | Immediate-release tablets containing combimetinib and methods of making and using the same | Dec 29, 2036 | Genentech Inc |
| Cotellic | US10590102 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone | Jun 30, 2036 | Genentech Inc |
| Cotellic |
US10590102 (Pediatric) | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone | Dec 30, 2036 | Genentech Inc |
| Cotellic | US11087354 | Combination therapies | Jun 22, 2034 | Genentech Inc |
| Cotellic |
US11087354 (Pediatric) | Combination therapies | Dec 22, 2034 | Genentech Inc |
| Cotellic | US11254649 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone | Jun 30, 2036 | Genentech Inc |
| Cotellic |
US11254649 (Pediatric) | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone | Dec 30, 2036 | Genentech Inc |
| Cotellic | US11597699 | MEK inhibitors and methods of their use | Oct 05, 2026 | Genentech Inc |
| Cotellic | US7803839 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | Nov 10, 2029 | Genentech Inc |
| Cotellic |
US7803839 (Pediatric) | Azetidines as MEK inhibitors for the treatment of proliferative diseases | May 10, 2030 | Genentech Inc |
| Cotellic | US8362002 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | Oct 05, 2026 | Genentech Inc |
| Cotellic |
US8362002 (Pediatric) | Azetidines as MEK inhibitors for the treatment of proliferative diseases | Apr 05, 2027 | Genentech Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳